Capecitabine in advanced hepatocellular carcinoma: A multicenter experience.
Administration, Metronomic
Antimetabolites, Antineoplastic
/ administration & dosage
Capecitabine
/ administration & dosage
Carcinoma, Hepatocellular
/ drug therapy
Dose-Response Relationship, Drug
Drug Monitoring
Drug-Related Side Effects and Adverse Reactions
/ therapy
Female
Humans
Italy
/ epidemiology
Liver Neoplasms
/ drug therapy
Male
Middle Aged
Neoplasm Staging
Retrospective Studies
Treatment Outcome
Capecitabine
Hepatocellular carcinoma
Systemic therapy
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
13
01
2019
revised:
04
04
2019
accepted:
19
06
2019
pubmed:
20
7
2019
medline:
22
5
2020
entrez:
20
7
2019
Statut:
ppublish
Résumé
Recent data suggest a potential activity and a good tolerability of capecitabine in advanced hepatocellular carcinoma (HCC). To evaluate capecitabine activity and safety in a wide cohort of advanced HCC patients. Retrospective analysis of 143 capecitabine-treated patients (January 2010 to December 2017) in three centers of the Veneto Oncology Network. Capecitabine was administered in second and third line, but also in first line instead of sorafenib in Child-Pugh B patients (70%), compromised clinical conditions (14%) or contraindications to antiangiogenetics (16%). Median overall survival (OS) and time to progression (TTP) were 6.9 and 2.8 months, respectively. There were no differences in OS and TTP between the 32 patients treated with non-metronomic scheme (2000 mg/day for 14 days) and the 111 patients treated with metronomic scheme (1000 mg/day) after correction for prognostic factors at baseline with a propensity score analysis. Capecitabine was more active in patients intolerant to sorafenib than in those progressing during treatment (p = 0.024). At least one adverse event (mainly hematological) was experienced by 73% of patients but discontinuation was necessary only in 11 (8%). Capecitabine can be considered an active and safe option in advanced HCC, especially for patients unfit for other treatments.
Sections du résumé
BACKGROUND
Recent data suggest a potential activity and a good tolerability of capecitabine in advanced hepatocellular carcinoma (HCC).
AIMS
To evaluate capecitabine activity and safety in a wide cohort of advanced HCC patients.
METHODS
Retrospective analysis of 143 capecitabine-treated patients (January 2010 to December 2017) in three centers of the Veneto Oncology Network.
RESULTS
Capecitabine was administered in second and third line, but also in first line instead of sorafenib in Child-Pugh B patients (70%), compromised clinical conditions (14%) or contraindications to antiangiogenetics (16%). Median overall survival (OS) and time to progression (TTP) were 6.9 and 2.8 months, respectively. There were no differences in OS and TTP between the 32 patients treated with non-metronomic scheme (2000 mg/day for 14 days) and the 111 patients treated with metronomic scheme (1000 mg/day) after correction for prognostic factors at baseline with a propensity score analysis. Capecitabine was more active in patients intolerant to sorafenib than in those progressing during treatment (p = 0.024). At least one adverse event (mainly hematological) was experienced by 73% of patients but discontinuation was necessary only in 11 (8%).
CONCLUSIONS
Capecitabine can be considered an active and safe option in advanced HCC, especially for patients unfit for other treatments.
Identifiants
pubmed: 31320302
pii: S1590-8658(19)30672-3
doi: 10.1016/j.dld.2019.06.015
pii:
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Capecitabine
6804DJ8Z9U
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1713-1719Informations de copyright
Copyright © 2019. Published by Elsevier Ltd.